SS-31 and cardiac function: an experimental study in dogs
SS-31 / elamipretide appears in scientific publications, but to properly understand a study, it must be clear what was actually tested. This article focuses on one original publication. We distinguish the measured outcome from possible applications in dogs, cats, and horses.
What was studied?
Dogs with experimentally induced heart failure.
What did the researchers report?
This study investigated elamipretide, also known as SS-31, in an experimental model of heart failure. The authors reported improvements in left ventricular function and several mitochondrial measurements.
What are the limitations?
Induced heart failure in research dogs differs from spontaneously occurring heart disease in veterinary practice. The results do not prove a general benefit in healthy or older dogs.
What does this mean for pet owners?
For pet owners, the distinction between research and treatment is particularly important. An experiment can clarify a biological mechanism without showing that an investigational product is suitable for a sick animal. The original publication is therefore a starting point for knowledge, not a set of instructions for use.
Which cardiac function was studied?
The study focused on the left ventricle and mitochondrial function in a heart failure model. These are specific outcomes; they do not provide a complete answer about lifespan or daily functioning.
Official research source
Source publication: Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Summary based on the consulted source data; not a complete systematic review.
For educational research information only. Investigational products are not intended for administration to humans or animals. This article does not constitute veterinary treatment advice; discuss health concerns with a veterinarian.